Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: LY3502970

First Posted Date: 2021-10-21

Last Posted Date: 2022-11-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 62

Registration Number: NCT05086445

Locations: 🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan
🇯🇵
Clinical Research Hospital Tokyo, Shinjuku-ku, Tokyo, Japan
🇯🇵
P-One Clinic, Hachioji, Tokyo, Japan

and more 2 locations

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back Pain

Phase 2

Completed

Conditions: Chronic Low-back Pain

Interventions: Drug: LY3526318
Drug: Placebo

First Posted Date: 2021-10-20

Last Posted Date: 2023-10-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 159

Registration Number: NCT05086289

Locations: 🇺🇸
VIN-Julie Schwartzbard, Aventura, Florida, United States
🇺🇸
Suncoast Research Group, Miami, Florida, United States
🇺🇸
New Horizon Research Center, Miami, Florida, United States

and more 25 locations

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis

Phase 2

Completed

Conditions: Osteoarthritis
Osteo Arthritis Knee

Interventions: Drug: LY3526318
Drug: Placebo

First Posted Date: 2021-10-18

Last Posted Date: 2024-07-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 160

Registration Number: NCT05080660

Locations: 🇺🇸
Alliance for Multispecialty Research, LLC Tempe, Tempe, Arizona, United States
🇺🇸
Clinvest Research LLC, Springfield, Missouri, United States
🇺🇸
Artemis Institute for Clinical Research, San Diego, California, United States

and more 24 locations

A Study of Baricitinib (LY3009104) in Children With COVID-19

Phase 3

Recruiting

Conditions: Covid19
Corona Virus Infection

Interventions: Drug: Baricitinib

First Posted Date: 2021-10-12

Last Posted Date: 2024-08-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT05074420

Locations: 🇺🇸
The University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
🇧🇷
Pesquisare Saude, Santo André, São Paulo, Brazil

and more 17 locations

A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Mirikizumab Autoinjector
Drug: Mirikizumab Prefilled Syringe

First Posted Date: 2021-10-06

Last Posted Date: 2022-07-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 237

Registration Number: NCT05069896

Locations: 🇺🇸
Covance Dallas, Dallas, Texas, United States
🇺🇸
LabCorp CRU, Inc., Daytona Beach, Florida, United States
🇺🇸
QPS, Springfield, Missouri, United States

A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus

Phase 1

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Sodium Citrate
Drug: Treprostinil
Drug: Humalog diluent
Drug: Magnesium Chloride

First Posted Date: 2021-10-05

Last Posted Date: 2023-10-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 40

Registration Number: NCT05067270

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
🇩🇪
Profil Mainz, Mainz, Germany

A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

Phase 2

Active, not recruiting

Conditions: Alzheimer Disease

Interventions: Drug: LY3372689
Drug: Placebo

First Posted Date: 2021-10-01

Last Posted Date: 2024-08-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 330

Registration Number: NCT05063539

Locations: 🇯🇵
Memory Clinic Toride, Toride, Ibaraki, Japan
🇦🇺
St Vincent's Hospital, Sydney, New South Wales, Australia
🇦🇺
Box Hill Hospital, Box Hill, Victoria, Australia

and more 65 locations

A Multiple Dose Study of LY3502970 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3502970
Drug: Esomeprazole

First Posted Date: 2021-09-21

Last Posted Date: 2022-04-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 26

Registration Number: NCT05051566

Locations: 🇬🇧
Quotient Clinical Ltd, Nottingham, United Kingdom

A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

Phase 2

Completed

Conditions: Obesity
Overweight and Obesity

Interventions: Drug: LY3502970
Drug: Placebo

First Posted Date: 2021-09-21

Last Posted Date: 2023-09-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 272

Registration Number: NCT05051579

Locations: 🇭🇺
DRC Gyógyszervizsgáló Központ, Balatonfüred, Veszprém, Hungary
🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Valley Clinical Trials, Inc., Northridge, California, United States

and more 32 locations

A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: LY3502970
Drug: Dulaglutide
Drug: Placebo

First Posted Date: 2021-09-17

Last Posted Date: 2023-10-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 383

Registration Number: NCT05048719

Locations: 🇸🇰
MEDI-DIA s.r.o., Sabinov, Prešovský Kraj, Slovakia
🇸🇰
Funkystuff, Nove Zamky, Slovakia
🇺🇸
Cotton O'Neil Clinical Research Center, Topeka, Kansas, United States

and more 41 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy